Integration of novel agents into combined-modality treatment for rectal cancer patients.
about
Postoperative adjuvant chemotherapy in rectal cancer operated for curePreclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancerIntensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum.Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis.Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatmentGender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.The current state of targeted agents in rectal cancer.Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I studyDosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boostInduction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated?New specific molecular targets for radio-chemotherapy of rectal cancer.Accomplishments in 2008 in the adjuvant treatment of rectal cancerHigh-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART).Preoperative intensified radiochemotherapy for rectal cancer: experience of a single institution.Gene expression signatures in the peripheral blood after radiosurgery of human cerebral arteriovenous malformations.Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064).Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation.Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.[Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma].Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients.
P2860
Q24201072-D9306D41-E985-428C-89CD-4CACC70FA6B2Q28252635-EE35E137-C471-4333-B6B2-DE3450209E43Q33421285-3BD75D57-D526-4DE0-9798-D5C2191263BDQ33776733-B55096B6-4FD3-4DC6-9AC1-69E4B5D92F0CQ34098024-87BBDD3E-3940-4B27-A53E-0A4F33FBAFF0Q34255956-D9DB06C3-1B04-4608-88BF-CB283C1AD5F6Q34943505-1638DF86-0F77-4DC2-8A50-E50B330D5872Q35001108-47117BA8-8AA1-4BE1-98D8-301192B3F92BQ35183525-CDB737F6-5AB0-424D-A6B5-A27A0B62245FQ35584836-534FFDE7-C8B4-48AD-B7F4-5079BDB1D4F5Q35996651-A859400B-96DE-4E7B-B8E1-929F20780853Q36112410-BAD7B8A0-406A-4AA4-B8FE-ABF2B97EC67CQ36905925-0EF7F3D0-9162-4903-A738-C777EA357D12Q37817000-0D612DBC-E13F-4750-B65F-0765119D323EQ38064748-A3D9AB89-5D0F-46E1-A4D6-DB64CEA01D0EQ41130691-133AF59A-38D8-455A-A5C9-51D9A7A4F9CBQ42002475-E1136C55-DA08-4718-A344-801BA8B3EE70Q43191379-789C3DAC-4080-414F-8B68-61CE25B8D05CQ44197593-CAD16892-606B-4366-A84C-FBA0B23E5A73Q44801406-7C655A0E-6F32-4AD3-915D-D5AC14E5D697Q45064952-75720662-42D8-41E1-9B96-52B0E6A52BE1Q47718910-20A8540F-1928-4313-8B47-D454269A04CCQ49381573-B7F68225-D12C-4C38-9CAE-C2A688D9DB98Q53724796-D88ABF3B-BE5B-4A90-94E2-220AAA0038AAQ54493763-D493FFD4-A5A3-4F1E-9977-A504EB1F1207Q55331295-86C65DFB-E892-47F4-864B-4B6AE6D53259
P2860
Integration of novel agents into combined-modality treatment for rectal cancer patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Integration of novel agents into combined-modality treatment for rectal cancer patients.
@ast
Integration of novel agents into combined-modality treatment for rectal cancer patients.
@en
type
label
Integration of novel agents into combined-modality treatment for rectal cancer patients.
@ast
Integration of novel agents into combined-modality treatment for rectal cancer patients.
@en
prefLabel
Integration of novel agents into combined-modality treatment for rectal cancer patients.
@ast
Integration of novel agents into combined-modality treatment for rectal cancer patients.
@en
P1476
Integration of novel agents into combined-modality treatment for rectal cancer patients.
@en
P2093
Rolf Sauer
P2888
P304
P356
10.1007/S00066-007-9000-9
P50
P577
2007-05-01T00:00:00Z